文献速递肾移植肾小球疾病

抗磷脂酶A2受体1抗体与肾移植后膜性肾病复发

Anti Phospholipase A2 Receptor 1 Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation.
PubMed 文献 · Kidney Int Rep · 2024-09-23

法国前瞻性多中心研究纳入72例等待并接受肾移植的膜性肾病患者,并建立65例回顾性验证队列,评估移植前抗PLA2R1抗体对膜性肾病复发的预后意义。前瞻队列中位随访23.5个月累积复发率26%,回顾队列中位随访67个月为28%;移植前抗PLA2R1抗体阳性与复发风险强相关(风险比=5.9;95%CI:2.3-15.7;P<0.0001),回顾队列证实该结果。移植后早期监测抗PLA2R1抗体价值有限,因复发多在移植后6个月内早期出现(中位延迟5[3-14]个月),尽管抗体水平下降。

要点

  • 移植前抗PLA2R1抗体阳性是移植肾膜性肾病复发的强预测因素(风险比=5.9)。
  • 膜性肾病移植后复发累积发生率在前瞻队列为26%,回顾队列为28%。
  • 复发多在移植后6个月内早期出现,中位延迟5个月,移植后早期抗体监测价值有限。

核心结论

  • 移植前存在抗PLA2R1抗体是移植肾膜性肾病复发的强预测因素。
  • 应考虑对抗PLA2R1相关膜性肾病的肾移植候选者进行个体化免疫监测和管理策略。

研究设计与样本

  • 法国前瞻性多中心研究,纳入72例等待并接受肾移植的膜性肾病患者。
  • 建立65例患者的回顾性验证队列。
  • 主要目的为评估移植前抗PLA2R1抗体对膜性肾病复发的预后意义。
  • 同时评估复发发生率、发生时间、危险因素及移植肾结局。

主要发现

  • 前瞻队列中位随访23.5个月,膜性肾病复发累积发生率为26%。
  • 回顾队列中位随访67个月,复发累积发生率为28%。
  • 移植前抗PLA2R1抗体与复发风险强相关(风险比=5.9;95%CI:2.3-15.7;P<0.0001),回顾队列证实。
  • 复发多在移植后6个月内早期出现,中位延迟5[3-14]个月,尽管抗体水平下降。
  • 移植后早期监测抗PLA2R1抗体价值有限。

临床怎么用

  • 对等待肾移植的膜性肾病患者,应检测移植前抗PLA2R1抗体以评估复发风险。
  • 对抗PLA2R1抗体阳性的移植候选者,考虑个体化免疫监测和管理策略。
  • 移植后早期抗体监测对预测复发价值有限,需关注移植后6个月内的早期复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Membranous nephropathy can lead to end-stage kidney disease, for which kidney transplantation is the preferred therapy. However, the disease often relapses, which can impact allograft survival. METHODS: We conducted a prospective multicenter study in France involving 72 patients with membranous nephropathy who were awaiting and then underwent kidney transplantation. In addition, we established a retrospective validation cohort of 65 patients. The primary objective was to evaluate the prognostic significance of pretransplant anti phospholipase A2 receptor 1 (PLA2R1) antibodies on the recurrence of membranous nephropathy. The study also assessed the incidence rate, time to onset, and risk factors for recurrence, as well as allograft outcome. RESULTS: The prospective cohort showed a 26% cumulative incidence of membranous nephropathy recurrence after a median follow-up of 23.5 months. This was confirmed by a 28% cumulative incidence after a median follow-up of 67 months in the retrospective cohort. A strong association was found between the presence of anti-PLA2R1 antibodies prior to transplantation and the risk of disease recurrence (risk ratio = 5.9; 95% confidence interval [CI]: 2.3-15.7; P < 0.0001). These results were confirmed in the retrospective cohort. Monitoring of anti-PLA2R1 antibodies in the immediate posttransplant period is of limited value, because recurrence occurred early in the first 6 months (median delay of 5 [3-14] months) after transplantation despite decreasing antibody levels. CONCLUSION: The presence of anti-PLA2R1 antibodies prior to transplantation was a strong predictor of recurrence of allograft membranous nephropathy. An individualized immunomonitoring and management strategy for kidney transplant candidates with anti-PLA2R1-associated membranous nephropathy should be considered.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Cremoni M, Teisseyre M, Thaunat O, et al. Anti Phospholipase A2 Receptor 1 Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation. Kidney Int Rep. 2024. PMID: 39698349. doi:10.1016/j.ekir.2024.09.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。